<DOC>
	<DOCNO>NCT02128334</DOCNO>
	<brief_summary>Eligard 6-month depot injection formulation combine active ingredient leuprorelin acetate ( LA ) biodegradable polymer matrix ( AtrigelÂ® delivery system ) . The 6-month ( 45 mg ) formulation approve Russian market 2009 . It show reduce testosterone prostate-specific antigen ( PSA ) level well tolerate several clinical trial . However , clinical trial limit strict patient inclusion exclusion criterion . Therefore , current non-interventional study aim investigate whether efficacy tolerability 6-month LA depot formulation could also confirm broad heterogeneous patient population encounter daily clinical practice Russian Federation . This study evaluate total serum PSA testosterone level , Quality Life ( QoL ) patient , demographic patient data , diagnosis diagnostic finding patient . It provide analysis different subgroup patient depend previous hormonal treatment anamnesis disease .</brief_summary>
	<brief_title>An Observational Study Looking How Well Drug Eligard Works How Well Tolerated Body Patients With Advanced Prostate Carcinoma Russian Federation</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>All male patient &gt; 18 year age advance PCa oncourologist decide prescribe Eligard 45 mg Patient participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Uro-Oncologists</keyword>
	<keyword>PSA</keyword>
	<keyword>Eligard</keyword>
	<keyword>prostate carcinoma</keyword>
</DOC>